ESR1 and breast cancer: To this end, we interrogated different dosing strategies in ER+ breast cancer cells expressing either wild-type estrogen receptor (WT-ER) or doxycycline (DOX)-induced expression of the ER Y537S LBD-activating mutation, which is one of the most prevalent and potent ESR1-activating mutations (16).